INS and diabetes mellitus: Therefore, we would like to increase the clinicians’ awareness of the risk of missing an opportunity to give effective CV-preventive drugs also to diabetes patients with longer duration, higher HbA1c, women and diabetes patients already on multiple diabetes treatments and insulin.